179 related articles for article (PubMed ID: 2402230)
1. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
Chu E; Lai GM; Zinn S; Allegra CJ
Mol Pharmacol; 1990 Sep; 38(3):410-7. PubMed ID: 2402230
[TBL] [Abstract][Full Text] [Related]
2. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
[TBL] [Abstract][Full Text] [Related]
3. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
Chu E; Zinn S; Boarman D; Allegra CJ
Cancer Res; 1990 Sep; 50(18):5834-40. PubMed ID: 1697502
[TBL] [Abstract][Full Text] [Related]
4. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
5. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
Johnston PG; Drake JC; Trepel J; Allegra CJ
Cancer Res; 1992 Aug; 52(16):4306-12. PubMed ID: 1643628
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
7. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
Schmidt W; Chaney SG
Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
[TBL] [Abstract][Full Text] [Related]
9. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
de Angelis PM; Fjell B; Kravik KL; Haug T; Tunheim SH; Reichelt W; Beigi M; Clausen OP; Galteland E; Stokke T
Int J Oncol; 2004 May; 24(5):1279-88. PubMed ID: 15067352
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
Aschele C; Sobrero A; Faderan MA; Bertino JR
Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
[TBL] [Abstract][Full Text] [Related]
12. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Chu E; Koeller DM; Johnston PG; Zinn S; Allegra CJ
Mol Pharmacol; 1993 Apr; 43(4):527-33. PubMed ID: 8474431
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of a fluorouracil-resistant human gastric carcinoma cell line and its morphological behavior].
Yue XF; Han JX; Dai ZQ; Liu MZ; Yang WY; Xu JY; Zhou JJ; Chen LJ; Zhang SY
Zhongguo Yao Li Xue Bao; 1993 Nov; 14 Suppl():S1-4. PubMed ID: 8010063
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.
Patel M; Ardalan K; Hochman I; Tian EM; Ardalan B
Anticancer Res; 2003; 23(1A):447-52. PubMed ID: 12680247
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
17. On the rational development of a new drug: the example of the fluorinated pyrimidines.
Heidelberger C
Cancer Treat Rep; 1981; 65 Suppl 3():3-9. PubMed ID: 7346154
[TBL] [Abstract][Full Text] [Related]
18. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
[TBL] [Abstract][Full Text] [Related]
19. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
[TBL] [Abstract][Full Text] [Related]
20. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]